PharMerica (NYS: PMC) reported earnings on Feb. 9. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), PharMerica met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly, and GAAP earnings per share expanded significantly.
Margins increased across the board.
PharMerica recorded revenue of $495.6 million. The nine analysts polled by S&P Capital IQ anticipated revenue of $501.6 million. GAAP sales were 0.8% higher than the prior-year quarter's $491.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.35. The nine earnings estimates compiled by S&P Capital IQ averaged $0.21 per share on the same basis. GAAP EPS of $0.26 for Q4 were 63% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 15.8%, 270 basis points better than the prior-year quarter. Operating margin was 4.0%, 180 basis points better than the prior-year quarter. Net margin was 1.6%, 60 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $509.6 million. On the bottom line, the average EPS estimate is $0.27.
Next year's average estimate for revenue is $2.00 billion. The average EPS estimate is $1.12.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 126 members rating the stock outperform and six members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give PharMerica a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PharMerica is hold, with an average price target of $15.71.
If you're interested in health care stocks like PharMerica, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.
Add PharMerica to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.